The present disclosure relates to aqueous compositions for anti-IL17a antibodies, and more particularly to aqueous compositions for anti-IL17a antibodies with a V.sub.HH variable domain and a V.sub.L variable domain, and can be used as a medicinal agent for treating IL-17A-mediated diseases.

A use that relates to mannuronic acid oligosaccharides or a composition comprising same in the treatment of Th1-dominance related diseases. The Th1-dominance related diseases may be selected from Multiple Sclerosis, Crohn's disease, Type I Diabetes, Rheumatoid Arthritis, Hashimoto's thyroiditis, vitiligo, Sjögren's Syndrome, Polycystic ovary syndrome, Celiac Disease and Grave's disease, preferably from Multiple Sclerosis, Crohn's disease and Rheumatoid Arthritis.

A use that relates to mannuronic acid oligosaccharides or a composition comprising same in the treatment of Th1-dominance related diseases. The Th1-dominance related diseases may be selected from Multiple Sclerosis, Crohn's disease, Type I Diabetes, Rheumatoid Arthritis, Hashimoto's thyroiditis, vitiligo, Sjögren's Syndrome, Polycystic ovary syndrome, Celiac Disease and Grave's disease, preferably from Multiple Sclerosis, Crohn's disease and Rheumatoid Arthritis.

The present invention belongs to the field of medicine, and specifically discloses an amino alcohol derivative represented by Formula I, a pharmaceutically acceptable salt, solvate, polymorph or prodrug thereof. In addition, the present invention also discloses a pharmaceutical composition comprising the above substances, and a use of the substance in the preparation of a medicament for the prevention and treatment of an immune inflammatory disease, or a disease or condition associated with immunological competence such as multiple sclerosis, ALS, CIDP, systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, psoriasis, polymyositis, etc.

The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.

The present invention provides methods and compositions for treating thyroid-related medical conditions. Many thyroid-related medical conditions exist that go undiagnosed and untreated. These conditions may be prevented and treated with reduced folates and vitamin B12. Administration of reduced folates and vitamin B12 will prevent or treat cerebrospinal folate deficiency, which is linked to thyroid-related medical conditions. Administration of reduced folates and vitamin B12 will also prevent or treat conditions associated with masked megaloblastic anemia and hypothyroidism, and other conditions brought upon through improper thyroid function. Additionally, it is commonplace to treat many thyroid conditions with anti-thyroid drugs or thyroid stimulating drugs. This practice alone is also responsible for causing, or not beneficially addressing, adverse conditions that can be prevented or treated through the methods and compositions discussed herein.

The present invention provides a 1,2,4-triazine-3,5-dione compound, a preparation method therefor, and an application thereof. The 1,2,4-triazine-3,5-dione compound having a structure represented by formula (I) provided by present invention has a selective agonistic effect on THRβ, and the activity, selectivity, and metabolic stability thereof have significant advantages over disclosed compounds, and can function as a therapeutic and/or preventive drug for thyroid hormone receptor related diseases, comprising, but not limited to, obesity, diabetes, hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, liver steatosis, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, familial hypercholesterolemia, dyslipidemia, atherosclerosis, hypothyroidism, and thyroid cancer.

The invention provides an antibody that can bind IGF-1R. The antibody is composed of light chain and heavy chain. The light chain and heavy chain variable regions are one of the combinations of SEQ ID NO:2 and SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11, SEQ ID NO:12 and SEQ ID No 13, SEQ ID NO:14 and SEQ ID NO:15. The invention also provides nucleic acid molecules encoding the antibody binding IGF-1R, vectors containing the nucleic acid, cells transformed by the vectors, and uses of these nucleic acids, vectors, and cells.

A compound represented by the following general formula (I) [the symbol in the formula are as defined in the description], a salt thereof, or the like is a RET inhibitor or RET tyrosine kinase inhibitor that can he used as an agent for the prevention or treatment of disorders including cancers and cancer metastasis having mutations in RET. ##STR00001##

A new and improved method for preparing maxacalcitol and an intermediate therefor is provided. The method is an efficient and cost-effective process for preparing maxacalcitol and an intermediate therefor.